The oncometabolite 2-hydroxyglutarate (2-HG) is a signature biomarker in various cancers, where it accumulates as a result of mutations in isocitrate dehydrogenase (IDH). The metabolic source of 2-HG, in a wide variety of cancers, dictates both its generation and also potential therapeutic strategies, but this remains difficult to access in vivo. Here, utilizing patient-derived chondrosarcoma cells harboring endogenous mutations in IDH1 and IDH2, we report that 2-HG can be rapidly generated from glutamine in vitro. Then, using hyperpolarized magnetic resonance imaging (HP-MRI), we demonstrate that in vivo HP [1-C] glutamine can be used to non-invasively measure glutamine-derived HP 2-HG production. This can be readily modulated utilizing a selective IDH1 inhibitor, opening the door to targeting glutamine-derived 2-HG therapeutically. Rapid rates of HP 2-HG generation in vivo further demonstrate that, in a context-dependent manner, glutamine can be a primary carbon source for 2-HG production in mutant IDH tumors.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5718944 | PMC |
| http://dx.doi.org/10.1016/j.cmet.2017.10.001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Oncogenic IDH1 drives robust loss of histone acetylation and increases chromatin heterogeneity.
Proc Natl Acad Sci U S A
January 2025
Department of Immunology and Regenerative Biology, Weizmann Institute of Science, Rehovot 7610001, Israel.
Malignant gliomas are heterogeneous tumors, mostly incurable, arising in the central nervous system (CNS) driven by genetic, epigenetic, and metabolic aberrations. Mutations in isocitrate dehydrogenase (IDH1/2) enzymes are predominantly found in low-grade gliomas and secondary high-grade gliomas, with IDH1 mutations being more prevalent. Mutant-IDH1/2 confers a gain-of-function activity that favors the conversion of a-ketoglutarate (α-KG) to the oncometabolite 2-hydroxyglutarate (2-HG), resulting in an aberrant hypermethylation phenotype.
View Article and Find Full Text PDFMapping the developmental trajectory of human astrocytes reveals divergence in glioblastoma.
Nat Cell Biol
January 2025
Department of Human Genetics, Emory University School of Medicine, Atlanta, GA, USA.
Glioblastoma (GBM) is defined by heterogeneous and resilient cell populations that closely reflect neurodevelopmental cell types. Although it is clear that GBM echoes early and immature cell states, identifying the specific developmental programmes disrupted in these tumours has been hindered by a lack of high-resolution trajectories of glial and neuronal lineages. Here we delineate the course of human astrocyte maturation to uncover discrete developmental stages and attributes mirrored by GBM.
View Article and Find Full Text PDFSpectrum of IDH-mutant tumors in Ollier-Maffucci disease: the triple interaction theory.
Orphanet J Rare Dis
November 2024
Sorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neuro-oncologie, Paris, France.
Article Synopsis
- The study aims to enhance understanding of tumor development in patients with Ollier disease (OD) and Maffucci syndrome (MS), focusing on IDH-mutated tumors and their origins.
- It proposes that a single IDH-mutant cell could lead to various tumors due to early embryonic mutations and that not all mutated cells will display the IDH mutant characteristics.
- Additionally, it suggests that specific genetic predispositions (SNPs) may increase the likelihood of developing particular tumors in these patients, linking developmental defects to tumor occurrence.
Detection of IDH mutation in glioma by desorption electrospray ionization (DESI) tandem mass spectrometry.
Sci Rep
November 2024
Department of Chemistry, Purdue University, West Lafayette, IN, 47907, USA.
Article Synopsis
- Desorption electrospray ionization (DESI) tandem mass spectrometry (MS) is utilized to determine the mutation status of isocitrate dehydrogenase (IDH) in human gliomas, which have poor surgical outcomes due to their diffuse nature.* -
- IDH mutations are clinically significant, as they correlate with better prognoses; the mutant enzyme converts alpha-ketoglutaric acid to 2-hydroxyglutarate, leading to abnormal accumulation in cells.* -
- The study evaluates two mass spectrometry methods for their effectiveness in differentiating between IDH-mutant and IDH-wildtype samples, finding that the triple quadrupole has slightly better sensitivity, which could assist in
Association between accumulation of 2-hydroxyglutarate detected by MR spectroscopy and preoperative seizure in IDH-mutant glioma.
J Neurosurg
October 2024
1Departments of Neurosurgery and.
Article Synopsis
- The study investigated the link between the oncometabolite 2-hydroxyglutarate (2HG) and preoperative seizures in patients with gliomas, particularly focusing on those with mutant isocitrate dehydrogenase (IDH) genes.
- It included 196 patients, measuring metabolite concentrations through 3T MR spectroscopy and assessing correlations with patient characteristics and tumor attributes.
- Results showed that IDH-mutant gliomas had a higher prevalence of preoperative seizures (57.8%) compared to IDH-wildtype gliomas (15.2%), and higher levels of 2HG were found in patients with preoperative seizures, suggesting its potential role in seizure activity.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!